A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer
Launched by WATER-JEL · May 11, 2012
Trial Information
Current as of May 05, 2025
Terminated
Keywords
ClinConnect Summary
All women will be given two types of Jell. One should be applied immediately after radiation and the second one, 3 times every day. All women will complete detailed questionnaire every two weeks and will be evaluated by the treating team at the same time.All women will be evaluated two weeks after end of radiation period.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Woman with histologically confirmed breast cancer who underwent lumpectomy and requires adjuvant radiation therapy with 2 Gy/fx to a total dose of 50 Gy.
- • 2. Women who received neoadjuvant or adjuvant chemotherapy are eligible for the study. Three weeks is the minimal interval between chemotherapy and start of radiation therapy.
- • 3. Patient able to understand the study designed and cooperate with instructions of use.
- • 4. Patient able to sign informed consent
- Exclusion Criteria:
- • 1. Woman with lactose allergy (lactose intolerance are eligible)
- • 2. Woman with known connective tissue disorder
- • 3. Woman with uncontrolled diabetes
- • 4. Patients receiving radiation protocol with 2.64 Gy/fx or 1.8 Gy/fx
- • 5. Woman who is unable to sign an informed consent
About Water Jel
Water-Jel Technologies is a leading provider of innovative wound care products and trauma management solutions, dedicated to enhancing patient outcomes through advanced medical technologies. With a focus on developing and delivering high-quality, effective, and user-friendly products, Water-Jel is committed to meeting the needs of healthcare professionals in emergency and clinical settings. The company's extensive portfolio includes burn dressings, cooling gels, and other wound care innovations, all designed to support rapid response to injuries and promote optimal healing. Water-Jel is also actively engaged in clinical research to further validate the efficacy of its products and contribute to the advancement of medical knowledge in trauma care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ramat Gan, , Israel
Patients applied
Trial Officials
Merav Ben David
Principal Investigator
La Sheba Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials